文献速递浆细胞疾病

骨髓瘤微小残留病阴性的预后价值:四项三期研究汇总分析

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
PubMed 文献 · Blood · 2022-01-01

基于POLLUX、CASTOR、ALCYONE和MAIA四项三期研究,汇总分析复发难治及不适合移植新诊断多发性骨髓瘤患者。

要点

  • ≥CR且MRD阴性是RRMM和不适合移植NDMM的PFS预后因素(HR 0.20)
  • 达雷妥尤单抗方案使更多患者达到≥CR且MRD阴性
  • MRD采用二代测序评估,灵敏度阈值10^-5

核心结论

  • ≥CR且MRD阴性是RRMM和不适合移植NDMM患者PFS的预后因素,且不受治疗或疾病背景影响。
  • 达雷妥尤单抗为基础的治疗与更多患者达到≥CR且MRD阴性相关。

研究设计与样本

  • 汇总POLLUX、CASTOR、ALCYONE和MAIA四项三期研究的患者水平数据。
  • MRD通过二代测序评估,灵敏度阈值10^-5。
  • 分析不适合移植NDMM及接受≤2线 prior 治疗的RRMM患者。
  • 中位随访:POLLUX 54.8个月,CASTOR 50.2个月,ALCYONE 40.1个月,MAIA 36.4个月。

主要发现

  • 达到≥CR且MRD阴性者较未达CR或MRD阳性者PFS改善(不适合移植NDMM和RRMM HR 0.20,P<.0001)。
  • 不适合移植NDMM和RRMM≤2线 prior 治疗者HR 0.20,P<.0001。
  • 时变Cox比例风险模型证实≥CR且MRD阴性与PFS改善相关。

关键数值与推荐

  • MRD阴性定义为二代测序检测灵敏度达10^-5。
  • ≥CR且MRD阴性者与未达CR或MRD阳性者相比,PFS的HR为0.20(P<.0001)。

临床怎么用

  • 可将≥CR且MRD阴性作为RRMM和不适合移植NDMM的PFS预后指标。
  • 达雷妥尤单抗为基础的治疗方案有助于提高≥CR且MRD阴性率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies improved MRD negativity rates and reduced the risk of disease progression or death by approximately half vs standards of care. We conducted a large-scale pooled analysis for associations between patients achieving complete response or better (≥CR) with MRD-negative status and progression-free survival (PFS). MRD was assessed via next-generation sequencing (10-5 sensitivity threshold). Patient-level data were pooled from all 4 studies and for patients with TIE NDMM and patients with RRMM who received ≤2 prior lines of therapy (≤2 PL). PFS was evaluated by response and MRD status. Median follow-up (months) was 54.8 for POLLUX, 50.2 for CASTOR, 40.1 for ALCYONE, and 36.4 for MAIA. Patients who achieved ≥CR and MRD negativity had improved PFS vs those who failed to reach CR or were MRD positive (TIE NDMM and RRMM hazard ratio [HR] 0.20, P < .0001; TIE NDMM and RRMM ≤2 PL HR 0.20, P < .0001). This benefit occurred irrespective of therapy or disease setting. A time-varying Cox proportional hazard model confirmed that ≥CR with MRD negativity was associated with improved PFS. Daratumumab-based treatment was associated with more patients reaching ≥CR and MRD negativity. These findings represent the first large-scale analysis with robust methodology to support ≥CR with MRD negativity as a prognostic factor for PFS in RRMM and TIE NDMM. These trials were registered at www.clinicaltrials.gov as #NCT02076009, #NCT02136134, #NCT02195479, and #NCT02252172.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cavo M, San-Miguel J, Usmani SZ, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022. PMID: 34289038. doi:10.1182/blood.2021011101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。